BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10499595)

  • 1. The oral fluoropyrimidines in cancer chemotherapy.
    Lamont EB; Schilsky RL
    Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
    Milano G; Ferrero JM; François E
    Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral fluoropyrimidines in the treatment of colorectal carcinoma].
    Porschen R
    Dtsch Med Wochenschr; 2003 Jun; 128 Suppl 2():S121-3. PubMed ID: 12817344
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UFT: mechanism of drug action.
    Köhne CH; Peters GJ
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):13-8. PubMed ID: 11098484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xeloda in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2001 Jun; 55(5):326-8. PubMed ID: 11452682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
    White RM
    J Clin Oncol; 2001 Jun; 19(11):2970. PubMed ID: 11387375
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
    Hosokawa A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.